Wynn Capital LLC Buys New Stake in Danaher Co. (NYSE:DHR)

Wynn Capital LLC bought a new stake in Danaher Co. (NYSE:DHR) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 1,572 shares of the conglomerate’s stock, valued at approximately $364,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BKM Wealth Management LLC acquired a new position in Danaher in the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher in the 4th quarter valued at $29,000. OFI Invest Asset Management acquired a new position in Danaher in the 3rd quarter valued at $30,000. Rakuten Securities Inc. acquired a new position in Danaher in the 4th quarter valued at $36,000. Finally, GHP Investment Advisors Inc. raised its holdings in Danaher by 540.0% in the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after acquiring an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock traded down $2.70 during trading on Wednesday, reaching $250.41. 3,064,441 shares of the company’s stock were exchanged, compared to its average volume of 2,783,958. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The company’s fifty day moving average price is $248.95 and its 200-day moving average price is $230.64. The firm has a market cap of $185.44 billion, a PE ratio of 39.12, a P/E/G ratio of 3.96 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the previous year, the firm posted $2.36 EPS. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. On average, research analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is 16.90%.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock valued at $8,265,802 over the last three months. Company insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DHR shares. Bank of America boosted their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada upped their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $270.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.